Literature DB >> 1383923

Competitive binding of a monoclonal antibody SZ-21 with anti-PLA1 antibodies and its potential for clinical application.

X Xi1, Y Zhao, H Jiang, Q Wu, P Li, C Ruan.   

Abstract

Both intact IgG and Fab fragments of a monoclonal antibody SZ-21, directed against platelet glycoprotein (GP) IIIa, inhibited binding of anti-PLA1 antibodies to PLA1-positive platelets in a dose dependent manner. Conversely, the binding capacity of the platelets for SZ-21 was decreased in the presence of anti-PLA1 antibodies. In Western blots, the determinant for SZ-21 was present on GPIIIa from either PLA1 or PLA2 homozygotes, but SZ-21 did not affect the interaction of anti-Yukb alloantibodies with their target antigen on GPIIIa. These results suggest that SZ-21 reacts with an epitope on the GPIIIa molecule very close to but not identical with that for anti-PLA1. The existence of PLA1-reactive alloantibodies in serum could be demonstrated by their competitive effect on the binding of SZ-21.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383923

Source DB:  PubMed          Journal:  Nouv Rev Fr Hematol


  3 in total

1.  Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab') in an in vivo mouse model of alloimmune thrombocytopenia.

Authors:  Tamam Bakchoul; Brian Boylan; Ulrich J H Sachs; Gregor Bein; Changgeng Ruan; Sentot Santoso; Peter J Newman
Journal:  Transfusion       Date:  2008-11-04       Impact factor: 3.157

2.  Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia.

Authors:  Huiying Zhi; Maria T Ahlen; Björn Skogen; Debra K Newman; Peter J Newman
Journal:  Blood Adv       Date:  2021-09-28

3.  Flow cytometric immunobead assay for quantitative detection of platelet autoantibodies in immune thrombocytopenia patients.

Authors:  Juping Zhai; Mengyuan Ding; Tianjie Yang; Bin Zuo; Zhen Weng; Yunxiao Zhao; Jun He; Qingyu Wu; Changgeng Ruan; Yang He
Journal:  J Transl Med       Date:  2017-10-23       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.